^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CCT301-59

    i
    Other names: CCT301-59, CCT301 59
    Associations

    News

    Trials
    Company:
    Exuma Biotech, Sunterra Biotech
    Drug class:
    ROR2-targeted CAR-T immunotherapy
    Associations

    News

    Trials
    over1year
    Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma (clinicaltrials.gov)
    P1/2, N=66, Terminated, Shanghai PerHum Therapeutics Co., Ltd. | Active, not recruiting --> Terminated; Adjustment of study strategy
    Trial termination • Metastases
    |
    AXL (AXL Receptor Tyrosine Kinase) • ROR2 (Receptor Tyrosine Kinase Like Orphan Receptor 2)
    |
    cyclophosphamide • CCT301-038 • CCT301-59
    over1year
    A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors (clinicaltrials.gov)
    P1, N=9, Terminated, Shanghai PerHum Therapeutics Co., Ltd. | N=18 --> 9 | Active, not recruiting --> Terminated; Adjustment of study strategy
    Enrollment change • Trial termination
    |
    ROR2 (Receptor Tyrosine Kinase Like Orphan Receptor 2)
    |
    cyclophosphamide • CCT301-59
    over4years
    Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma (clinicaltrials.gov)
    P1/2, N=66, Active, not recruiting, Shanghai PerHum Therapeutics Co., Ltd. | Trial completion date: Mar 2035 --> Jun 2023 | Trial primary completion date: Jan 2021 --> Jun 2022
    Clinical • Trial completion date • Trial primary completion date
    |
    AXL (AXL Receptor Tyrosine Kinase) • ROR2 (Receptor Tyrosine Kinase Like Orphan Receptor 2)
    |
    CCT301-038 • CCT301-59